Genelux (NASDAQ:GNLX) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Genelux (NASDAQ:GNLX – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04), Zacks reports.

Genelux Stock Up 2.9%

NASDAQ GNLX traded up $0.06 on Monday, reaching $1.92. The stock had a trading volume of 277,007 shares, compared to its average volume of 256,074. The firm has a market capitalization of $86.87 million, a price-to-earnings ratio of -2.23 and a beta of 0.68. Genelux has a 12-month low of $1.77 and a 12-month high of $5.89. The stock has a fifty day moving average price of $2.31 and a two-hundred day moving average price of $2.65.

Insiders Place Their Bets

In other news, CEO Thomas Zindrick sold 34,463 shares of Genelux stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.67, for a total value of $92,016.21. Following the completion of the sale, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at approximately $3,274,560.09. The trade was a 2.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Yong Yu sold 9,683 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.75, for a total value of $26,628.25. Following the completion of the sale, the insider owned 258,688 shares in the company, valued at $711,392. This represents a 3.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 47,903 shares of company stock worth $126,320 over the last 90 days. 7.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on GNLX shares. Lucid Cap Mkts raised shares of Genelux to a “strong-buy” rating in a research report on Wednesday, September 16th. Wall Street Zen upgraded Genelux from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research note on Thursday, October 15th. Finally, Benchmark reissued a “speculative buy” rating on shares of Genelux in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Read Our Latest Stock Report on Genelux

About Genelux

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

Read More

Earnings History for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.